Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 10/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 10/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31145148 | 0.70 | CHRNB4 (0.41) | CHRNB4CHRNA3CHRNA7ALDH1A1MAPT | |
| SCHEMBL29081728 | 0.69 | CHRNB4 (0.47) | CHRNB4CHRNA3CHRNA7ALDH1A1MAPT | |
| SCHEMBL926871 | 0.68 | NAMPT (0.46) | NAMPTALDH1A1HSD17B10 | |
| SCHEMBL24365292 | 0.68 | CHRNB4 (0.40) | CHRNB4CHRNA3CHRNA7ALDH1A1TSHR | |
| SCHEMBL31145105 | 0.68 | CHRNB4 (0.40) | CHRNB4CHRNA3CHRNA7ALDH1A1TSHR | |
| SCHEMBL31500084 | 0.67 | CHRNB4 (0.45) | CHRNB4CHRNA3CHRNA7ALDH1A1HSD17B10 | |
| SCHEMBL24672520 | 0.66 | CHRNB4 (0.57) | CHRNB4CHRNA3CHRNA7ALDH1A1MAPT | |
| SCHEMBL30812588 | 0.66 | CHRNB4 (0.57) | CHRNB4CHRNA3CHRNA7ALDH1A1MAPT | |
| SCHEMBL12637458 | 0.66 | ALDH1A1 (0.42) | NAMPTALDH1A1HSD17B10TSHRCYP1A2 | |
| SCHEMBL12637453 | 0.66 | NAMPT (0.47) | NAMPTALDH1A1HSD17B10MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHRNB4 3299/4885CHRNA3 2163/4885CHRNA7 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.